Iqvia Holdings Inc (NYSE:IQV) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC lowered its stake in shares of Iqvia Holdings Inc (NYSE:IQV) by 30.5% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 39,719 shares of the medical research company’s stock after selling 17,423 shares during the quarter. SG Americas Securities LLC’s holdings in Iqvia were worth $5,933,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the stock. Montag & Caldwell LLC boosted its position in Iqvia by 3.3% during the 3rd quarter. Montag & Caldwell LLC now owns 2,840 shares of the medical research company’s stock valued at $424,000 after purchasing an additional 90 shares during the period. Appleton Partners Inc. MA boosted its position in Iqvia by 2.6% during the 3rd quarter. Appleton Partners Inc. MA now owns 13,204 shares of the medical research company’s stock worth $1,972,000 after acquiring an additional 338 shares during the period. Parallel Advisors LLC boosted its position in Iqvia by 61.7% during the 3rd quarter. Parallel Advisors LLC now owns 828 shares of the medical research company’s stock worth $124,000 after acquiring an additional 316 shares during the period. Rosenblum Silverman Sutton S F Inc. CA boosted its position in Iqvia by 4.5% during the 3rd quarter. Rosenblum Silverman Sutton S F Inc. CA now owns 30,929 shares of the medical research company’s stock worth $4,620,000 after acquiring an additional 1,325 shares during the period. Finally, Picton Mahoney Asset Management boosted its position in Iqvia by 4.9% during the 3rd quarter. Picton Mahoney Asset Management now owns 174,700 shares of the medical research company’s stock worth $26,097,000 after acquiring an additional 8,195 shares during the period. Institutional investors and hedge funds own 89.92% of the company’s stock.

Shares of IQV traded down $0.25 during midday trading on Friday, reaching $137.59. The stock had a trading volume of 1,439,592 shares, compared to its average volume of 1,291,668. Iqvia Holdings Inc has a 52 week low of $104.90 and a 52 week high of $164.13. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.12 and a quick ratio of 1.14. The firm’s 50 day moving average price is $146.83 and its 200-day moving average price is $148.24. The company has a market capitalization of $27.14 billion, a P/E ratio of 26.87, a P/E/G ratio of 1.55 and a beta of 0.87.

Iqvia (NYSE:IQV) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $1.60 EPS for the quarter, topping the Zacks’ consensus estimate of $1.57 by $0.03. Iqvia had a return on equity of 16.95% and a net margin of 2.24%. The company had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.76 billion. During the same quarter in the previous year, the business earned $1.42 EPS. The company’s quarterly revenue was up 6.7% compared to the same quarter last year. On average, equities analysts forecast that Iqvia Holdings Inc will post 5.9 earnings per share for the current year.

A number of research analysts have issued reports on IQV shares. Credit Suisse Group boosted their price target on Iqvia from $165.00 to $170.00 and gave the stock an “outperform” rating in a research report on Thursday, July 25th. Barclays set a $180.00 price target on Iqvia and gave the stock a “buy” rating in a research report on Monday, July 15th. JPMorgan Chase & Co. boosted their price target on Iqvia from $160.00 to $180.00 and gave the stock an “overweight” rating in a research report on Thursday, July 25th. ValuEngine lowered Iqvia from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Finally, Wells Fargo & Co boosted their price target on Iqvia from $170.00 to $178.00 and gave the stock an “outperform” rating in a research report on Thursday, July 25th. Four analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. Iqvia presently has a consensus rating of “Buy” and an average price target of $166.46.

Iqvia Company Profile

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Featured Article: Fiduciary

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.